Yahoo
Shanghai - Delayed Quote CNY

Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)

15.46 +0.18 (+1.18%)
At close: 3:00:01 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
11,423,813.90
11,875,013.01
11,005,794.90
13,245,133.30
14,951,252.69
Cost of Revenue
4,404,653.36
4,399,990.37
4,427,650.74
4,218,281.87
4,232,510.43
Gross Profit
7,019,160.54
7,475,022.64
6,578,144.16
9,026,851.43
10,718,742.27
Operating Expense
5,509,820.89
5,999,510.70
5,760,492.90
7,801,592.81
8,805,848.03
Operating Income
1,509,339.65
1,475,511.93
817,651.26
1,225,258.62
1,912,894.24
Net Non Operating Interest Income Expense
-117,952.71
-115,373.45
-122,968.64
-91,738.29
-113,974.28
Pretax Income
454,366.68
533,955.47
-365,291.56
394,556.78
-1,259,388.63
Tax Provision
329,257.89
341,657.92
337,103.09
242,691.58
331,594.34
Net Income Common Stockholders
281,828.92
360,784.86
-553,797.94
318,973.32
-1,529,744.21
Basic EPS
0.28
0.34
-0.51
0.29
-1.38
Diluted EPS
0.28
0.34
-0.51
0.29
-1.38
Basic Average Shares
1,047,189.19
1,056,161.76
1,083,753.31
1,106,010.14
1,106,025.75
Diluted Average Shares
1,047,189.19
1,056,161.76
1,083,753.31
1,106,010.14
1,106,025.75
Total Operating Income as Reported
479,083.23
566,108.74
-246,754.18
436,018.84
-1,249,459.48
Rent Expense Supplemental
4,457.37
3,164.67
4,590.37
3,726.21
3,256.44
Total Expenses
9,914,474.25
10,399,501.08
10,188,143.64
12,019,874.68
13,038,358.46
Net Income from Continuing & Discontinued Operation
281,828.92
360,784.86
-553,797.94
318,973.32
-1,529,744.21
Normalized Income
930,228.02
954,941.18
162,188.74
858,125.23
758,927.16
Interest Income
3,252.36
4,836.85
7,525.04
18,823.38
19,873.68
Interest Expense
119,206.23
118,700.55
129,588.55
109,931.40
135,099.94
Net Interest Income
-117,952.71
-115,373.45
-122,968.64
-91,738.29
-113,974.28
EBIT
573,572.91
652,656.02
-235,703.02
504,488.18
-1,124,288.69
EBITDA
573,572.91
1,166,960.42
382,612.78
1,097,063.06
-626,726.35
Reconciled Cost of Revenue
4,404,653.36
4,399,990.37
4,427,650.74
4,218,281.87
4,232,510.43
Reconciled Depreciation
591,993.29
514,304.40
618,315.79
592,574.88
497,562.33
Net Income from Continuing Operation Net Minority Interest
281,828.92
360,784.86
-553,797.94
318,973.32
-1,529,744.21
Total Unusual Items Excluding Goodwill
-864,532.13
-792,208.43
-954,648.90
-718,869.21
-3,051,561.83
Total Unusual Items
-864,532.13
-792,208.43
-954,648.90
-718,869.21
-3,051,561.83
Normalized EBITDA
1,438,105.04
1,959,168.85
1,337,261.68
1,815,932.27
2,424,835.47
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-216,133.03
-198,052.11
-238,662.23
-179,717.30
-762,890.46
12/31/2022 - 11/18/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: